Abstract: The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.

Abstract: The invention relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. It has been found that compositions combining a statin and a cannabinoid are improved over existing statin formulations. The compositions of the invention for example allow for a lower effective dose of statin and a reduction of the adverse effects seen with statins taken alone. Dosing ranges and formulations suitable for oral, buccal, and sublingual administration are disclosed. Various specific cannabinoids such as cannabidiol and synthetic cannabidiols selected for their anti-inflammatory, antioxidant, and anti-atherosclerotic effect are shown to be particularly advantageous.

Abstract: The present invention provides a drug capable of preventing or treating diabetic nephropathy. The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RAR? agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.

Abstract: Disclosed herein is a method of treating or preventing motion sickness or at least one symptom thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant.

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

Abstract: An antiseptic solution comprising a pH-dependent antimicrobial agent, the pH-dependent antimicrobial agent having an operative pH range, wherein the solution has a pH on storage that is lower than the operative pH range. Applicators for applying the antiseptic solution and methods of using the antiseptic solution and applicators are also provided.

Abstract: The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.

Abstract: Provided are methods and compositions for preventing, reducing, mitigating and treating pain, particularly neuropathic pain by the combined administration of an agent that increases EETs and an agent that reduces/inhibits endoplasmic reticulum (ER) stress.

Abstract: The present invention relates to: a pharmaceutical composition for preventing or treating LDL cholesterol-related diseases, containing a ribosome-binding preparation; a food composition; and a method for preventing or treating LDL cholesterol-related diseases by using the composition. According to the present invention, the ribosome-binding preparation selectively increases the expression of an LDL receptor in intestinal epithelial cells so as to promote LDL absorption in blood and tissue, such that LDL level in the blood can be reduced, thereby being useful for preventing or treating various LDL cholesterol-related diseases including LDL hypercholesterolemia, hyperlipidemia, hypertension and apoplexy.

Abstract: The invention provides 4-piperidin-chroman-7-sulfonamide derivatives and salts thereof that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.

Abstract: Provided herein are pharmaceutical compositions comprising a vesicular monoamine transporter 2 (VMAT2) inhibitor (e.g., deutetrabenazine) and an excipient useful for treating stuttering in a subject in need thereof. Further provided are methods of treating stuttering in a subject in need thereof comprising administering an effective amount of a pharmaceutical composition of the present disclosure. Also provided herein are kits comprising such pharmaceutical compositions.

Abstract: This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a pharmaceutical composition for the treatment of cartilage disease which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.

Abstract: This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid.

Abstract: Stevia extracts with selected major steviol glycosides (Reb A, stevioside, Reb D, Reb C) and minor steviol glycosides and glycosylated diterpene derivative plant molecules, derived from Stevia rebaudiana plant are found to improve the perception of flavor and taste perception, which includes the sweet, savory and salty perception in a wide range of food and beverage applications.

Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition.

Abstract: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.

Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.

Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance recovery from soft tissue trauma, including both acute and non-acute soft tissue trauma. Enhanced recovery includes reduced recovery time and enhanced soft tissue healing.